Pain is a fundamental experience with sensory, emotional and cognitive aspects. Though pain is often a normal part of the human condition, in the clinical setting, there is vast inter-individual variability in the severity of pain reported by patients with apparently similar pain states, as well as widely differing analgesic dosing requirements to produce excellent pain relief with tolerable side-effects. This variability in pain sensitivity and the response to analgesic manipulations remains a considerable clinical challenge as well as an area of intense scientific investigation ([@A8583R1], [@A8583R2]). This inter-individual variability is a result of genetic factors, environmental factors, as well as the complex interaction of the two. Genetic variation has been shown to explain a significant portion of this variability. However, the fact is that studies of genetic differences in pain-related traits have been largely neglected. Heritability estimates based on inbred strains of laboratory mice studies suggest that genetic factors explain up to 30 to 76% of the variance in pain responding ([@A8583R3], [@A8583R4]). Twin studies suggest that genetic factors contribute to the differences in individuals' pain-related phenotypes with heritability estimates of up to 70% for clinical pain conditions and up to 60% for sensitivity to certain kinds of experimental stimuli ([@A8583R5]-[@A8583R7]). The identification of genetic variations affecting propensity to pain raises the possibility of discovering new therapeutic targets for pain. To date a large number of candidate 'pain' genes have been identified as potentially contributing to heritable differences in pain sensitivity and analgesic responsiveness in animals and humans. Since then, many genetic association studies have been conducted in humans to investigate the possibility that single nucleotide polymorphisms (SNPs) in an individual gene that may explain these differences. Single functional SNPs or combinations of SNP alleles that are generally tend to be inherited together (haplotypes) can contribute to increased or decreased susceptibility to pain. SNPs in more than 20 genes that affect pain sensitivity or analgesic responses have been identified in the human genome. These are summarized in [Table](#tbl657){ref-type="table"}. However, the study of pain-related SNPs in the human yield conflicting conclusions; in many cases, a finding from one has been contradicted by those from others. One example of these genes is Catechol-O-methyl Transferase (COMT). COMT is involved in the inactivation of the endogenous catecholamine neurotransmitters, playing key roles in the physiological modulation of analgesia and pain processing. It has been estimated that variations in the gene coding for COMT explain approximately 10% of variability in pain sensitivity ([@A8583R8]). A functional valine-to-methionine SNP at position 158 in COMT gene (called rs4680) has been proposed to contribute significantly increased experimental pain responses ([@A8583R9]). The form of the enzyme containing methionine is much less active in the brain than the one containing valine. The enzyme with increased activity has higher ability to activate μ-opioid neurotransmission in basal ganglia, thalamus, limbic and paralimbic areas in response to a sustained pain challenge resulting in decreased pain sensation ([@A8583R10]). The mu-opioid receptor gene (OPRM1) A118G polymorphism is another promising candidate for both opioid response and pain sensitivity because of both pain-related biological functions and apparent experimental and clinical evidence. A118G SNP of the OPRM1 gene is demonstrated to be associated with responses to three different experimental pain modalities, including thermal, mechanical, and ischemic pain ([@A8583R11]). Experimental short duration heat also shows the effects of TRPA1 variations on pain sensitivity ([@A8583R12]). Sensitivity to analgesics, including gabapentin, morphine, and NSAIDS, is also affected by genetic factors ([@A8583R13]). For example, polymorphisms of the cytochrome P450 enzymes (CYP), which play a key role in the metabolism of many drugs, can affect the efficacy of opiates and NSAIDs. Depending on the activity of the metabolites compared to the original drug, reduced activity of cytochromes can either reduce or enhance analgesic efficacy. For example, O-desmethyltramadol, which is one metabolite of the opioid tramadol, is a considerably more potent agonist of the µ-opioid receptor than tramadol. This means that reduced metabolization of tramadol display reduced analgesia, despite an increased half-life of tramadol being observed. Polymorphisms in the gene coding for cytochrome P450 2D6 (CYP2D6), which reduces its activity, is associate with reduced tramadol metabolism and effectiveness of this analgesic ([@A8583R8]). Furthermore, the variations in the melanocortin-1 receptor gene have been shown to affect µ-opioid analgesia in both mice and humans ([@A8583R9]). It is demonstrated that polymorphisms affecting the activity of the multidrug resistance protein ABCB1 (MDR1), which is a major determinant of morphine bioavailability, can alter the efficacy of morphine pain relief ([@A8583R10]). By affecting the rate of morphine and its metabolites removal from the cell this polymorphism alters the efficacy this analgesic. The control of pain has been a major goal of pharmacotherapy from the earliest times. Inter-individual variability in pain sensitivity and analgesic drug responsiveness in the clinical setting appears to be underpinned by complex interactions between multiple genetic and environmental factors ([@A8583R14]). Identification of genetical variations of alleles that affect the pharmacokinetics or pharmacodynamics of medications used for pain management gives the opportunity to the physicians to select the appropriate analgesic drug and dosing regimen for an individual patient, instead of empirical selection and dosing escalation ([@A8583R15], [@A8583R16]). These data emphasize the need to understand how genes influence individuals' response to pain and analgesic drug. In addition to its basic intellectual values, understanding the influence of genetic variation on pain sensitivity, variable responses is also highly clinically valuable as it may lead to more individualized care for patients and the identification of novel therapeutic targets. In the near future, pharmacogenomic approaches offer the field of pain medicine the opportunity to gain new insights into the pathophysiology of differences in individuals' analgesic responses and pain sensitivity ([@A8583R17]). If we open and collaborative approach to performing the relatively large studies required for reliable genetic analysis, this approach may provide new insights into pain treatments.

###### SNPs Suggested to Affect Human Pain Sensitivity and Analgesic Response

  Gene         Protein                                                  Mutation                 Phenotype                                                Example Refrences
  ------------ -------------------------------------------------------- ------------------------ -------------------------------------------------------- ----------------------------
  **LTA**      Lymphotoxin-alpha                                        Multiple SNPs            Altered pain sensitivity                                 ([@A8583R18])
  **PTGS2**    Prostaglandin-endoperoxide synthase 2                    Multiple SNPs            Altered pain sensitivity                                 ([@A8583R18])
  **SCN9A**    Sodium channel, voltage-gated, type IX, alpha subunit.   SNP                      Increased pain                                           ([@A8583R19], [@A8583R20])
  **COMT**     Catechol-O-methyltransferase                             Multiple SNPs            Increased/decreased pain sensitivity                     ([@A8583R12], [@A8583R21])
  **GCH1**     GTP cyclohydrolase                                       Multiple SNPs            Partial analgesia                                        ([@A8583R22])
  **OPRM1**    Opioid receptor m1                                       Multiple SNPs            Decreased pain sensitivity, decreased opioid analgesia   ([@A8583R11])
  **OPRD1**    Opioid receptor d1                                       Multiple SNPs            Increased/decreased pain sensitivity                     ([@A8583R23])
  **MC1R**     Melanocortin 1 receptor                                  Loss of function SNPs?   Partial analgesia, increased analgesic responsiveness    ([@A8583R24])
  **TRPA1**    Transient receptor potential A1                          Multiple SNPs            Increased pain sensitivity                               ([@A8583R12])
  **TRPV1**    Transient receptor potential V1                          SNP                      Decreased pain sensitivity                               ([@A8583R23])
  **CYP2D6**   Cytochrome P450 2D6                                      Multiple SNPs            Altered analgesic efficacy                               ([@A8583R8])
  **ABCB1**    ATP-binding cassette, B1                                 SNP                      Altered morphine sensitivity                             ([@A8583R10])
  **FAAH**     Fatty acid amide hydrolase                               Multiple SNPs            Increased pain sensitivity                               ([@A8583R12])

**Implication for health policy/practice/research/medical education:** Pharmacogenomics approaches offer the field of pain medicine the opportunity to gain new insights into the pathophysiology of differences in individuals' analgesic responses and pain sensitivity.
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